TAM
ALXN

Tiverton Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Tiverton Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-7,526
Closed -$986K – 753
2019
Q2 		$986K Buy
7,526
+3,859
+105% +$497K 0.04% 268
2019
Q1 		$496K Buy
3,667
+514
+16% +$63.9K 0.02% 340
2018
Q4 		$307K Sell
3,153
-648
-17% -$76.6K 0.02% 273
2018
Q3 		$528K Hold
3,801
– – 0.03% 241
2018
Q2 		$472K Buy
3,801
+1,528
+67% +$179K 0.02% 248
2018
Q1 		$253K Sell
2,273
-1,260
-36% -$151K 0.02% 286
2017
Q4 		$423K Buy
+3,533
New +$430K 0.03% 251

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Tiverton Asset Management's ALXN Position: Q3 2019 in Review

Tiverton Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2019, closing a stake of 7,526 shares — an estimated $986K sold.

Tiverton Asset Management first reported a position in ALXN in Q4 2017 and held it in 7 quarters. The position peaked at $986K in Q2 2019. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • Tiverton Asset Management reported no remaining Alexion Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Tiverton Asset Management sold 7,526 Alexion Pharmaceuticals shares in Q3 2019, an estimated $986K.
  • Tiverton Asset Management first reported a position in Alexion Pharmaceuticals in Q4 2017 and held it in 7 quarters.
  • Tiverton Asset Management's Alexion Pharmaceuticals position peaked at $986K in Q2 2019.
  • 648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.